Practical use of idarucizumab
The number of patients with indications for direct oral anticoagulants (DOACs) to prevent thrombotic events is steadily growing. However, in 1,1-2,2% of cases, ischemic strokes occur within DOAC therapy. In this case, DOAC use is a limitation for systemic thrombolysis, except for available reversal...
Saved in:
Main Authors: | G. R. Ramazanov, E. A. Kovaleva, E. V. Klychnikova, S. S. Petrikov, N. A. Shamalov, I. S. Aliev, E. V. Shevchenko |
---|---|
Format: | Article |
Language: | Russian |
Published: |
«SILICEA-POLIGRAF» LLC
2023-11-01
|
Series: | Кардиоваскулярная терапия и профилактика |
Subjects: | |
Online Access: | https://cardiovascular.elpub.ru/jour/article/view/3774 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Systemic Thrombolytic Therapy for Ischemic Stroke in the Course of Anticoagulants
by: L. Kh.-B. Akhmatkhanova, et al.
Published: (2021-11-01) -
Dabigatran etexilate in patients with nonvalvular atrial fibrillation: benefits of application in certain clinical situations
by: E. I. Baranova, et al.
Published: (2019-11-01) -
New safety standards for anticoagulant therapy in the treatment of atrial fibrillation
by: E. I. Baranova
Published: (2018-11-01) -
Anticoagulant-related bleeding in patients with heart failure in combination with chronic obstructive pulmonary disease and atrial fibrillation. Experience with Idarucizumab
by: L. A. Shpagina, et al.
Published: (2020-06-01) -
Pharmacokinetics and bioequivalence of the generic and original dabigatran etexilate after a single dose in healthy volunteers
by: V. B. Vasilyuk, et al.
Published: (2024-10-01)